Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-901-0 | CAS number: 5538-94-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
There are no studies available to assess the reproductive toxicity potential of the substance. However, there is a reliable two-generation study on rats available for a structurally similar substance. Exposure of rats to the substance at concentrations of 300, 750 aand 1500 ppm in the diet for two generations resulted in well-defined parental and postnatal toxicity at 1500 ppm without any adverse effects on reproductive performance. The NOEL was 750 ppm for both parents and offspring, indicating that there was no increased risk to the offspring in the absence of indications of adult toxicity based on body weight gain effects in the F1 generation.
Link to relevant study records
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 May 1988 - 15 August 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- not specified
- GLP compliance:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch No.of test material: B-1889
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Twenty eight male and 28 female weanling rats (F0 generation) were exposed to the substance by dietary inclusion for a total of 10-week pre-breed exposure period. Exposures continued through mating, gestation, parturition and lactation. Exposures continued through mating, gestation, parturition and lactation of the second litters.
- Details on mating procedure:
- Following a 10-week pre-breed exposure period the F0 rats were randomly paired within dose groups for a three week mating period to produce the F1A generation. At least 10 days after the weaning of the F1A litters, the Fo parents were paired again (with different male-female pairing within the dose groups than employed for the F1A breed) for 3 weeks to produce the F1B generation.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of the substance in the test diets was determined using gas chromatography. For the first 4 weeks of teh study, test diets from all diets were analysed for concentrations of the substance prior to administration of the diets to the animals. For the remaining 60 weeks of teh study, all test diets from every fourth preparation were analysed after administration of the diets to the study animals. Homogeneity and stability analyses of the substance in the diets were performed prior to the start of the test diet administration.
- Details on study schedule:
- Following a 10-week pre-breed exposure period the F0 rats were randomly paired within dose groups for a three week mating period to produce the F1A generation. At least 10 days after the weaning of the F1A litters, the F0 parents were paired again (with different male-female pairing within the dose groups than employed for the F1A breed) for 3 weeks to produce the F1B generation. After the F1B pups were weaned, the F0 animals were necropsied and high dose and control animals were examined for histopathologic lesions. At weaning, 28 F1B weanlings/sex/group were randomly selected as parents of the subsequent generation. Selected F1 parents were exposed to the same dietary concentrations of the substance as their parents for at least 10 weeks. After their pre-breed exposure the F1 animals were paired to produce F2A and F2B offspring.
- Dose / conc.:
- 0 ppm
- Dose / conc.:
- 300 ppm
- Dose / conc.:
- 750 ppm
- Dose / conc.:
- 1 500 ppm
- No. of animals per sex per dose:
- 28/sex/dose
- Control animals:
- yes, plain diet
- Details on study design:
- Twenty eight F0 rats/sex/dose were bred twice to produce F1A and F1B litters. Selected males and females from F1B litters were used as parents of the F2 generation. Twenty eight F1 pups/sex/dose, exposed to the same dietary concentration of the substance as their parents, were subsequently bred twice to produce F2A and F2B litters.
- Parental animals: Observations and examinations:
- PARAMETERS EXAMINED
The following parameters were examined in F0 to produce F1A/F1B litters and F1 to produce F2A/F2B litters: Mating index (males), mating index (males), fertility index (females) and fertility index (males). - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1A/F1B / F2A/F2B offspring: gestational index, live birth index, 4-day survival index (precull and postcull), 14-day survival index, 21-day survival index, lactation index, 28-day survival index.
[number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities, anogenital distance (AGD), presence of nipples/areolae in male pups, other:]
GROSS EXAMINATION OF DEAD PUPS:
[no / yes, for external and internal abnormalities; possible cause of death was/was not determined for pups born or found dead.] - Statistics:
- The unit of comparison was the male, pregnant female or the litter. Results of the qunatitative continuous variables (e.g. body weights, food consumption, organ weights, etc) were intercompared for the three treatment groups and one control group by use of Levene's test for equal variances; analysis of variance (ANOVA) and t-tests. When Levene's test indicated homogeneous variances and the ANOVA was significant, the pooled t-test was used for pair-wise comparisons. When Levene's test indicated heterogeneous variances, all groups were compared by an ANOVA for unequal variances followed, when necessary, by the separate variance t-test for pairwise comparisons. The significance levels for the t-tests comparisons were corrected by the Bonferroni method. Nonparametric data were statistically evaluated using the Kruskal-Wallis test followed by the Mann-Whitney U test for pairwise comparisons when appropriate. Frequency data were compared using the Fisher's exact test. For all statistical tests, the fidcial limit of 0.5 (two-tailed) was used as the criterion for statistical significance.
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced body weight and body weight gain at the top concentration begining one week after treatment.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Substantial reductions in food consumption were observed throughout the pre-breed period in F0 animals at the top concentration.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Gestational length as well as mating, fertility and gestational indices were unaffected by treatment. Body weights and bodyu weight gains at 300 and 750 ppm were essentially equivalent to control values throughout gestation. Gestational food consumption was unaffected by treatment. There were no differences across the groups for reproductive parameters for F0 parents for the F1A and F1B breeds.
- Clinical signs:
- effects observed, non-treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Males and females at 1500 ppm exhibited consistently reduced body weights throughout the entire treatment period. Significant weight gain depression was noted at 1500 ppm.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Food consumption for the F1 males and females was reduced at 1500 ppm throughout the treatment period. No effects on food consumption were noted in F1 males and females at 300 and 750 ppm.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Maternal gestational body weights, but not weight gains, were reduced at 1500 ppm.
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 750 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Clinical signs:
- effects observed, non-treatment-related
- Mortality / viability:
- mortality observed, non-treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Pup body weights and body weight gains were unaffected by treatment though lactational day 7. From day 14 through weaning on lactational day 21, and postweaning, on day 28, body weights of male and female pups at 1500 ppm were reduced. Corresponding body weight gains for lactational days 7-21 and 21-28 (postweaning) were reduced at 1500 ppm. Body weights and weight gains of pups at 750 and 300 ppm were unaffected by treatment.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- 750 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Reproductive performance
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Clinical signs:
- effects observed, non-treatment-related
- Mortality / viability:
- mortality observed, non-treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- F2B pup body weights per litter were equivalent through lactational day 4. From lactational day 7 through weaning on day 21, and postweaning, on day 28, body weights of F2B pups at 1500 ppm were reduced. Concurrent F2B pup weight gain reductions were observed at 1500 ppm from day 4-28. There were no observable effects of treatment on body weight at 750 and 300 ppm.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOEL
- Generation:
- F2
- Effect level:
- 750 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F2
- Effect level:
- 1 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Reproductive effects observed:
- no
- Lowest effective dose / conc.:
- 1 500 ppm
- Treatment related:
- no
- Conclusions:
- Exposure of rats to the substance at concentrations of 300, 750 aand 1500 ppm in the diet for two generations resulted in well-defined parental and postnatal toxicity at 1500 ppm without any adverse effects on reproductive performance. The NOEL was 750 ppm for both parents and offspring, indicating that there was no increased risk to the offspring in the absence of indications of adult toxicity.
- Executive summary:
The potential of the substance to produce alterations in parental fertility, maternal pregnancy and lactation, and growth and development of the offspring for two generations and two litters per generation was evaluated in Sprague Dawley rats. The substance was administered via the diet at concentrations of 300, 750 aand 1500 ppm. A well-defined parental and postnatal toxicity as evidenced by body weight reductions occurred at 1500 ppm without any adverse effects on reproductive performance. The NOEL was 750 ppm for both parents and offspring, indicating that there was no increased risk to the offspring in the absence of indications of adult toxicity.
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 500
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Sufficient to address requirements.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
In a reliable developmental toxicity study the substance were administered to pregnant rats for 10 days at doses of 10, 25 and 50 mg/kg bw/day. There were no deleterious effects on gestation, but the substances did cause more dams to resorb one or more fetuses at the 50 mg/kg bw/day dose level. No teratological findings could be ascribed to the substances employed at doses up to 50 mg/kg bw/day in rats when dosed during GD 6 to 15.
In a reliable developmental toxicity study for a structurally similar substance, rats were administered the substance by oral gavage on GD 6 to 15 at doses of 1, 10 and 20 mg/kg bw/day. Treatment related clinical signs of toxicity was observed at 10 and 20 mg/kg bw/day. These adverse effects were audible respiration and gasping at 10 and 20 mg/kg bw/day, and reduced body weight and food consumption at 20 mg/kg bw/day. The NOEL for maternal toxicity was 1 mg/kg bw/day. The NOEL for developmental toxicity was at least 20 mg/kg bw/day (the highest dose tested).
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not specified.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- Lot numbers:
Bardac-20: B35307 (25%)
Bardac-LF: B3414 (50%) - Species:
- rat
- Strain:
- Wistar
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- Adult female rats were mated with young adult males and detection of the vaginal sperm plug was considered to occur on day 0 of gestation.
- Duration of treatment / exposure:
- GD 6 to 15
- Frequency of treatment:
- Once daily.
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Bardac-20:
10 mg/kg bw/day - 25 females
25 and 50 mg/kg bw/day - 24 females
Bardac-LF:
10 mg/kg bw/day - 26 females
25 mg/kg bw/day - 23 females
50 mg/kg bw/day - 26 females - Control animals:
- yes, concurrent vehicle
- other: Aspirin (250 mg/kg bw/day)
- Maternal examinations:
- Body weights were recorded on days 0, 6, 11, 15 and 20 of gestation. All animals were observed daily for appearance and behaviour with particular attention to food consumption and weight, in order to rule out any abnormalities which may have occurred as a result of anorexic effects.
- Ovaries and uterine content:
- Uterine contentts were examined and the number of implantation sites for each uterine horn were recorded. Number of live pups, dead pups and resorption sies were also recorded. The weight of each pup and number of corpora lutea was recorded.
- Fetal examinations:
- The urogenital tract was examined for signs of gross abnormality. One third of the pups in each litter were randomly chosen and fixed in Bouin's solution and these animals were examined for soft tissue abnormalities. All pups showing any gross abnormality were included in this preparation.
- Statistics:
- Incidence of occurrence ratios of treated groups were compared with the ratio for the control group using confidence Belts for Proportions (confidence coefficient of 0.95). Fetus weights were evaluated by analyses of variance and compared to the control value sing Scheffe's test.
- Clinical signs:
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- not specified
- Total litter losses by resorption:
- effects observed, non-treatment-related
- Early or late resorptions:
- not specified
- Changes in pregnancy duration:
- not specified
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- not specified
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- number of abortions
- total litter losses by resorption
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- not specified
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not specified
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The most common abnormalities were hemorrhagic thorax and abdomen and gastroschisis. The incidence of accurrence was no greater in substance ttreated groups than in the controls.
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- external malformations
- skeletal malformations
- visceral malformations
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 50 mg/kg bw/day
- Conclusions:
- No teratological findings could be ascribed to the substances employed at doses up to 50 mg/kg bw/day in rats when dosed during GD 6 to 15.
- Executive summary:
The substance was administered to pregnant rats for 10 days at doses of 10, 25 and 50 mg/kg bw/day. There were no deleterious effects on gestation, but the substances did cause more dams to resorb one or more fetuses at the 50 mg/kg bw/day dose level. No teratological findings could be ascribed to the substances employed at doses up to 50 mg/kg bw/day in rats when dosed during GD 6 to 15.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 February 1990 - 23 February 1990
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1981
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-3 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 1984
- GLP compliance:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch No.of test material: B-1889
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Stability under test conditions: Stability was assessed prior to the start of the study. Solutions were prepared twice during the study and were analysed for test substance content prior to use.
- Solubility and stability of the test substance in the solvent/vehicle: Soluble in deionised water. - Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: males - 63 days old; females - 56 days old.
- Weight at study initiation: males - 250 - 300 g; females - 175 - 200 g
- Housing: stainless steel wire mesh cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 66-82°F
- Humidity (%): 40-74%
- Photoperiod (hrs dark / hrs light): 12 hour light period.
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Purity of substance was 80.8% and the dosing was adjusted to take into account the purity.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability was assessed prior to the start of the study. Solutions were prepared twice during the study and were analysed for test substance content prior to use employing gas chromatography.
- Duration of treatment / exposure:
- GD 6 to GD 15
- Frequency of treatment:
- Once daily
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Twenty five pregant females/dose
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- Clinical observations were recorded daily and twice daily during dosing. Maternal body weights were recorded for all females on GD 0, 6, 9, 12, 15, 18 and 21. Maternal food consumption was measured at 3-day intervals throughout gestation, GD 0-21.
- Ovaries and uterine content:
- At scheduled sacrifice on GD 21, the dams were evaluated for body weight, liver and gravid uterine weight, number of corpora lutea and number and status of implantation sites (i.e., early and late resorptions, dead fetuses, live fetuses).
- Fetal examinations:
- All live fetuses were dissected from the uterus, counted, sexed, weighed and examined for external malformations (including cleft palate) and variations. Approximately one-half of the fetuses in each litter were examined for visceral (including carniofacial) malformations and variations. The remaining one-half of the fetuses were evaluated for skeletal malformations and variations.
- Statistics:
- The unit of comparison was the pregnant female or the litter. Results of the quantitative continous variables (e.g. maternal body weights, organ weights, fetal weights etc) were intercompared for teh three treatment groups and vehicle control group by use of Levene's test for equal variance analysis of variance (ANOVA) and t-tests and Bonferroni probabilities for pairwise comparisons. When Levene's test indicated homogeneous variances and the ANOVA was significant, the pooled t-test was used. When Levene's test indicated heterogeneous variances, all groups were compared by an ANOVA for unequal variances followed, when necessary, by the separate variance t-test. Nonparametric data were statistically evaluated using the Kruskal-Wallis test followed by the Mann-Whitney U test for pairwise comparisons when appropriate. Incidence data were compared using the Fisher's exact test. For all statistical tests, the probability value of P<0.05 (two-talied) was used as the critical level of significance.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- This included audible respiration and gasping at 20 mg/kg bw/day and audible respiration at 10 mg/kg bw/day. At 20 mg/kg bw/day, audible respiration was observed subsequent to the treatment period as well.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There was a reduction in maternal body weight for says 12, 15, 18 and 21 at 20 mg/kg bw/day, bjt this was not statistically significant. Body weight gains also appeared to be decreased for days 9 to 12, 12 to 15 and 6-15 at 20 mg/kg bw/day and body weight gains appear reduced for the entire gestational period, day 0-21.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Reductions in food consumption at 20 mg/kkg bw/day for days 9 to 12, 12 to 15 and 6 to 15 correlate well with reductions in body weight and severity of clinical signs during the treatment period.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Gravid uterine weight and liver weight were unaffected by treatment.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Ulceration of the stomach and gas-filled intestines at 20 mg/kg bw/day.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not specified
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not specified - Changes in number of pregnant:
- not specified
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- clinical signs
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were two skeletal variations, poorly ossified cervical centrum and majority of proximal hindlimb phalanges unossified were significantly decreased in the 10 and 20 mg/kg bw/day groups, respectively. However, these were not considered to be related to treatment.
- Visceral malformations:
- no effects observed
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 20 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Developmental effects observed:
- no
- Conclusions:
- Administration of the substance by oral gavage to Sprage Dawley rats during organogenesis (GD 6 to 15) at doses of 1, 10 and 20 mg/kg bw/day resulted in characteristic maternal toxicity at 10 and 20 mg/kg bw/day. These adverse effects were audible respiration and gasping at 10 and 20 mg/kg bw/day, and reduced body weight and food consumption at 20 mg/kg bw/day. The NOEL for maternal toxicity was 1 mg/kg bw/day. The NOEL for developmental toxicity was at least 20 mg/kg bw/day (the highest dose tested).
- Executive summary:
The potential of the substance to cause developmental toxicity was evaluated in Sprague Dawley rats. The animals were administered the substance by oral gavage on GD 6 to 15 at doses of 1, 10 and 20 mg/kg bw/day. Treatment related clinical signs of toxicity was observed at 10 and 20 mg/kg bw/day. These adverse effects were audible respiration and gasping at 10 and 20 mg/kg bw/day, and reduced body weight and food consumption at 20 mg/kg bw/day. The NOAEL for maternal toxicity was 1 mg/kg bw/day. The NOEL for developmental toxicity was at least 20 mg/kg bw/day (the highest dose tested).
Referenceopen allclose all
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 20 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Sufficient to address requirements.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the findings of a reliable two generation reproductive toxicity study and a developmental toxicity study conducted on a structurally similar substance, together with the findings from a reliable developmental toxicity study conducted on the substance itself, classification of the substance is not justified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.